Vitamin D3 or D2: Which Form, and How Much
D3 raises blood levels more effectively than D2, daily dosing beats large intermittent doses, and the target is a measured status rather than a fixed dose.
The Short Answer
Three questions settle vitamin D supplementation, and the form is the easiest of them. D3, cholecalciferol, raises and maintains 25-hydroxyvitamin D more effectively than D2, ergocalciferol, which makes it the default. The more consequential questions are dosing pattern, where daily moderate doses outperform large intermittent ones, and target, where the useful goal is a measured status rather than a number of international units.
D3 Against D2
The chemistry. D3 is cholecalciferol, produced in skin from ultraviolet B exposure and found in animal sources. D2 is ergocalciferol, derived from fungal and yeast sources, which makes it the vegan option unless a lichen-derived D3 is used.
The comparison. Head-to-head trials and meta-analyses consistently find D3 raises serum 25-hydroxyvitamin D more effectively than an equivalent dose of D2, and maintains it longer. Proposed reasons include differences in binding protein affinity and in metabolic clearance.
The practical conclusion. Use D3 unless a plant source is required, in which case lichen-derived D3 is available and preferable to D2. Where D2 is used, a higher dose is needed for the same effect.
What does not matter much: capsule against liquid against spray, provided the dose is achieved. D is fat-soluble, so taking it with a fat-containing meal improves absorption, which matters more than the delivery format.
This is one of the simpler comparisons in supplementation, and it is worth getting right because it is the most commonly supplemented nutrient.
Dosing Pattern Matters More Than Form
| Pattern | Evidence |
|---|---|
| Daily moderate dose | Preferred. Respiratory infection benefit in individual participant data was seen with daily rather than bolus dosing |
| Weekly equivalent dose | Reasonable where daily adherence is poor |
| Monthly or annual large bolus | Some trials reported increased falls and fractures with large intermittent doses |
| Very high daily doses | No additional benefit demonstrated; hypercalcaemia risk at sustained high intake |
The bolus finding is the most useful and least known item here. Several trials of large intermittent doses reported adverse outcomes including increased falls, which is the opposite of the intended effect and is a reason to prefer daily dosing even though bolus dosing is more convenient.
The mechanism proposed involves the physiological difference between a steady state and repeated large peaks, and the practical conclusion is straightforward: daily, moderate, with food.
On magnesium: the enzymes that activate vitamin D require magnesium, and intake is commonly low. That is a reasonable argument for adequate magnesium alongside rather than for a proprietary combination product.
The Target Is a Status, Not a Dose
The most common error in this area is supplementing a fixed dose without measuring, in either direction.
Why status varies so much for a given dose: body weight and adiposity, since vitamin D distributes into fat; baseline status; skin tone, which affects cutaneous synthesis; latitude and season; sun exposure behaviour; age, since synthesis capacity declines; malabsorption; and some medications.
What to measure: serum 25-hydroxyvitamin D, which reflects status. The active form, 1,25-dihydroxyvitamin D, is tightly regulated and is not a status measure.
Where thresholds sit. Definitions of insufficiency and sufficiency differ between guideline bodies, which is a genuine disagreement rather than confusion. Values below around 25 to 30 nmol/L are widely regarded as low and associated with skeletal consequences; the region between there and roughly 50 nmol/L is where bodies disagree; and there is no evidence that pushing well above the sufficient range confers additional benefit.
The practical approach: measure, dose to correct if low, re-measure at three months, then set a maintenance dose. Test at both ends of the year at higher latitudes, since the seasonal swing is substantial and a fixed year-round dose is a compromise between two seasons.
What the Trials Actually Support
Being precise here matters, because vitamin D has been studied extensively with mostly modest results.
Well supported: correcting genuinely low status prevents skeletal consequences, and a severe, prolonged shortfall causes rickets and osteomalacia. This is the established case.
Reasonably supported: a reduction in acute respiratory infection risk, with individual participant data suggesting the effect concentrates in people whose baseline status was low and with daily rather than bolus dosing.
Weakly supported or neutral: large trials of supplementation in generally replete populations have returned neutral results for cardiovascular events, cancer incidence, diabetes prevention, cognitive decline and fracture reduction. That is not a failure of the nutrient; it is what happens when you supplement people who were already sufficient.
The interpretive lesson: observational associations between low vitamin D and almost every disease are abundant, and much of that reflects reverse causation and confounding, since ill people go outdoors less and adiposity lowers circulating levels.
What follows: vitamin D is a correction rather than an enhancement. Where status is low, correcting it is worthwhile and cheap. Where it is adequate, supplementing more does not appear to add anything.
Safety and Interactions
Hypercalcaemia is the main risk at sustained very high intake, presenting with nausea, constipation, confusion, kidney stones and, if prolonged, kidney damage. It requires substantially more than usual supplemental doses over a long period, and cases occur, generally from very high-dose self-administration or dosing errors.
Conditions requiring caution: primary hyperparathyroidism, sarcoidosis and other granulomatous diseases, and some lymphomas, where vitamin D metabolism is dysregulated and supplementation can raise calcium. Hypercalcaemia from any cause is a contraindication until investigated.
Kidney disease, where active forms may be required instead and the decision belongs with a clinician.
Interactions: thiazide diuretics raise calcium; some antiepileptics and glucocorticoids increase vitamin D metabolism, raising requirements; orlistat and bile acid sequestrants reduce absorption of fat-soluble vitamins.
Vitamin K2 is often recommended alongside, on the reasoning that D raises calcium availability while K2 activates matrix Gla protein and osteocalcin to direct it to bone. The mechanism is sound and the trial evidence is limited, which makes it a reasonable rather than an established addition.
Calcium supplements are a separate decision, and dietary calcium is preferred given the cardiovascular signal reported with supplements.
A Practical Protocol
Measure 25-hydroxyvitamin D before deciding a dose, and note the season.
Use D3, or lichen-derived D3 if a plant source is needed. D2 requires a higher dose for the same effect.
Dose daily rather than in large boluses, with a fat-containing meal.
Correct if low, then re-measure at three months and set a maintenance dose from the result.
Adjust seasonally at higher latitudes, with a higher winter dose and a lower or absent summer one, ideally guided by testing at both ends of the year.
Ensure adequate magnesium, since the activating enzymes require it and intake is commonly low.
Do not chase a high level. There is no demonstrated benefit above the sufficient range and there is a risk at sustained very high intake.
Consider K2 alongside, on mechanistic grounds, accepting that the trial evidence is limited.
Discuss with a clinician if you have kidney disease, hyperparathyroidism, sarcoidosis, or any history of hypercalcaemia or kidney stones.
The AEONNN Perspective
Vitamin D is the compound AEONNN corrects most often and the clearest illustration of correction against enhancement. Large trials in generally replete populations returned neutral results across cardiovascular, cancer, diabetes and cognitive endpoints, and the respiratory infection benefit concentrated in people whose baseline status was low. That pattern is the reason the platform measures before dosing.
Two Pharmacokinetics points decide the practical protocol. D3 raises and maintains 25-hydroxyvitamin D more effectively than D2, and daily moderate dosing outperforms large intermittent boluses, several trials of which reported increased falls. Daily, moderate, with a fat-containing meal, and adequate magnesium since the activating enzymes require it.
The target is a measured status rather than a dose, because status for a given dose varies with body weight and adiposity, skin tone, latitude, season, age and absorption. The Contingency layer adjusts it seasonally at higher latitudes, where a fixed year-round dose is a compromise between two seasons. And the Safety layer carries the specific exclusions: hyperparathyroidism, sarcoidosis, kidney disease and any history of hypercalcaemia.
Pillar Matrix mapping
Structural and Musculoskeletal Support, Inflammation and Immune Defense
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Pharmacokinetics Layer (HMDB, PubChem)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Safety Layer (DrugBank, FAERS)
Frequently Asked
Is D3 better than D2?
Yes. Head-to-head trials and meta-analyses consistently find D3 raises and maintains serum 25-hydroxyvitamin D more effectively. Lichen-derived D3 is the plant-source option.
Is daily or weekly dosing better?
Daily moderate dosing is preferred. Several trials of large intermittent boluses reported adverse outcomes including increased falls, and the respiratory infection benefit was seen with daily dosing.
What should I aim for?
A measured status rather than a fixed dose. Guideline bodies genuinely disagree on thresholds, and there is no evidence that pushing well above the sufficient range adds benefit.
Why do large vitamin D trials show nothing?
They largely enrolled people who were already sufficient. Vitamin D is a correction rather than an enhancement, and correcting genuinely low status is where the benefit sits.
Does magnesium matter for vitamin D?
The enzymes that activate vitamin D require magnesium, and intake is commonly low, which is a reasonable argument for adequate magnesium alongside.
Should I take K2 with it?
The mechanism is sound, since D raises calcium availability while K2 activates the proteins that direct it to bone. The trial evidence is limited, so it is reasonable rather than established.
Who should be cautious?
Anyone with primary hyperparathyroidism, sarcoidosis or other granulomatous disease, kidney disease, or a history of hypercalcaemia or kidney stones.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.